Free Trial
→ CODE RED: AI Meltdown Imminent? (From Paradigm Press) (Ad)tc pixel Free KRYS Stock Alerts

Krystal Biotech (KRYS) Financials

Krystal Biotech logo
$314.88 +2.30 (+0.74%)
As of 03:08 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Krystal Biotech

Annual Income Statements for Krystal Biotech

This table shows Krystal Biotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.15 -7.92 -11 -19 -32 -70 -140 11 89 205
Consolidated Net Income / (Loss)		 -1.15 -7.92 -11 -19 -32 -70 -140 11 89 205
Net Income / (Loss) Continuing Operations		 -1.15 -7.92 -11 -19 -32 -70 -140 11 89 205
Total Pre-Tax Income 		-1.15 -7.92 -11 -19 -32 -70 -140 13 95 189
Total Operating Income		 -1.14 -4.77 -12 -22 -33 -68 -145 -110 66 161
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 48 270 366
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 51 291 389
Operating Revenue		 - - - - - 0.00 0.00 51 291 389
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.09 20 23
Operating Cost of Revenue		 - - - - - 0.00 - 3.09 20 23
Total Operating Expenses		 1.14 4.77 12 22 33 68 145 157 205 205
Selling, General & Admin Expense		 0.40 1.56 4.16 6.47 15 40 78 98 114 147
Research & Development Expense		 0.74 3.21 7.76 16 18 28 42 46 54 58
Other Special Charges / (Income)		 - - - - 0.00 0.00 25 13 38 0.00
Total Other Income / (Expense), net		 -0.01 -3.15 1.03 2.99 0.83 -1.30 5.22 123 30 28
Interest & Investment Income		 - - - - - 0.20 5.22 23 30 28
Other Income / (Expense), net		 -0.01 -3.15 1.03 - 0.83 0.00 0.00 100 0.00 0.00
Income Tax Expense		 - - - - - 0.00 0.00 1.97 6.20 -15
Basic Earnings per Share		 ($1.31) ($1.48) ($0.97) ($1.20) ($1.71) ($3.13) ($5.49) $0.40 $3.12 $7.08
Weighted Average Basic Shares Outstanding		 877.49K 10.31M 11.20M 15.90M 18.79M 22.20M 25.49M 27.15M 28.59M 28.94M
Diluted Earnings per Share		 ($1.31) ($1.48) ($0.97) ($1.20) ($1.71) ($3.13) ($5.49) $0.39 $3.00 $6.84
Weighted Average Diluted Shares Outstanding		 877.49K 10.31M 11.20M 15.90M 18.79M 22.20M 25.49M 27.75M 29.74M 29.95M
Weighted Average Basic & Diluted Shares Outstanding		 877.49K 5.36M 11.20M 15.90M 18.79M 25.76M - 28.29M 28.81M 29.23M

Quarterly Income Statements for Krystal Biotech

This table shows Krystal Biotech's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 81 8.69 0.93 16 27 45 36 38 79 51 56
Consolidated Net Income / (Loss)		 81 8.69 0.93 16 27 45 36 38 79 51 56
Net Income / (Loss) Continuing Operations		 81 8.69 0.93 16 27 45 36 38 79 51 56
Total Pre-Tax Income 		81 11 0.93 16 30 49 44 47 48 51 61
Total Operating Income		 -26 3.14 -6.68 8.57 22 41 36 39 41 44 54
Total Gross Profit		 8.56 39 43 64 77 86 83 89 94 101 110
Total Revenue		 8.56 42 45 70 84 91 88 96 98 107 116
Operating Revenue		 8.56 42 45 70 84 91 88 96 98 107 116
Total Cost of Revenue		 0.00 3.09 2.42 6.01 6.68 4.95 5.03 7.17 4.26 6.59 6.32
Operating Cost of Revenue		 - - 2.42 6.01 6.68 4.95 5.03 7.17 4.26 6.59 6.32
Total Operating Expenses		 34 36 50 56 55 45 47 50 52 56 56
Selling, General & Admin Expense		 24 25 26 28 29 31 33 35 38 41 41
Research & Development Expense		 11 11 11 16 14 14 14 14 15 15 15
Total Other Income / (Expense), net		 107 7.52 7.62 7.48 7.30 7.23 7.35 7.47 6.59 6.70 7.75
Interest & Investment Income		 6.74 - 7.62 7.48 7.30 - 7.35 7.47 6.59 6.70 7.75
Income Tax Expense		 0.00 - 0.00 0.48 2.59 - 7.86 8.44 -31 -0.27 5.51
Basic Earnings per Share		 $2.88 $0.53 $0.03 $0.54 $0.95 $1.60 $1.24 $1.33 $2.74 $1.77 $1.91
Weighted Average Basic Shares Outstanding		 28.04M 27.15M 28.30M 28.60M 28.72M 28.59M 28.82M 28.91M 28.95M 28.94M 29.29M
Diluted Earnings per Share		 $2.79 $0.61 $0.03 $0.53 $0.91 $1.53 $1.20 $1.29 $2.66 $1.69 $1.83
Weighted Average Diluted Shares Outstanding		 28.89M 27.75M 29.29M 29.64M 29.90M 29.74M 29.87M 29.75M 29.83M 29.95M 30.51M
Weighted Average Basic & Diluted Shares Outstanding		 28.21M 28.29M 28.56M 28.73M 28.76M 28.81M 28.90M 28.94M 29.00M 29.23M 29.48M

Annual Cash Flow Statements for Krystal Biotech

This table details how cash moves in and out of Krystal Biotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.92 48 54 84 81 73 -179 196 -13 151
Net Cash From Operating Activities		 -1.31 -3.89 -9.45 -19 -26 -48 -101 -89 123 201
Net Cash From Continuing Operating Activities		 -1.31 -3.89 -9.45 -19 -26 -48 -101 -89 123 201
Net Income / (Loss) Continuing Operations		 -1.15 -7.92 -11 -19 -32 -70 -140 11 89 205
Consolidated Net Income / (Loss)		 -1.15 -7.92 -11 -19 -32 -70 -140 11 89 205
Depreciation Expense		 0.00 0.02 0.14 1.09 1.85 1.85 2.64 5.01 5.97 5.72
Amortization Expense		 - - - - - 0.92 0.74 0.90 0.75 0.83
Non-Cash Adjustments To Reconcile Net Income		 0.04 3.51 0.79 1.31 3.31 17 33 -67 73 17
Changes in Operating Assets and Liabilities, net		 -0.20 0.50 0.51 -2.00 0.93 2.05 2.66 -38 -45 -27
Net Cash From Investing Activities		 -0.02 -0.21 -10 -4.99 -11 -227 -114 83 -163 -58
Net Cash From Continuing Investing Activities		 -0.02 -0.21 -10 -4.99 -11 -227 -114 83 -163 -58
Purchase of Property, Plant & Equipment		 -0.02 -0.21 -2.23 -6.40 -15 -68 -53 -12 -4.24 -12
Purchase of Investments		 - - -8.09 -9.09 -3.21 -190 -319 -509 -458 -423
Sale of Property, Plant & Equipment		 - - - - - - - 0.00 0.00 0.44
Divestitures		 - - - - - 0.00 0.00 100 0.00 0.00
Sale and/or Maturity of Investments		 - - - 11 6.87 32 258 503 299 376
Net Cash From Financing Activities		 3.25 52 74 108 118 348 35 203 27 8.71
Net Cash From Continuing Financing Activities		 3.25 52 74 108 118 348 35 203 27 8.71
Issuance of Common Equity		 0.10 42 74 108 118 356 29 160 0.00 0.00
Other Financing Activities, net		 - - - - 0.00 -7.96 6.36 43 27 8.71
Effect of Exchange Rate Changes		 - - - - 0.00 0.00 -0.04 -0.16 -0.46 0.29
Cash Income Taxes Paid		 - - - - - - 0.00 0.00 5.67 16

Quarterly Cash Flow Statements for Krystal Biotech

This table details how cash moves in and out of Krystal Biotech's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 97 -15 0.68 -13 28 -29 -36 45 39 104 5.01
Net Cash From Operating Activities		 -21 -7.23 16 -4.17 59 53 31 53 40 78 80
Net Cash From Continuing Operating Activities		 -21 -7.23 16 -4.17 59 53 31 53 40 78 80
Net Income / (Loss) Continuing Operations		 81 8.69 0.93 16 27 45 36 38 79 51 56
Consolidated Net Income / (Loss)		 81 8.69 0.93 16 27 45 36 38 79 51 56
Depreciation Expense		 1.14 1.52 1.43 1.84 1.34 1.36 1.41 1.35 1.40 1.56 1.52
Amortization Expense		 0.23 -1.95 0.18 0.19 0.19 0.19 0.22 0.19 0.35 0.06 0.20
Non-Cash Adjustments To Reconcile Net Income		 -94 10 20 24 18 12 -20 12 11 13 13
Changes in Operating Assets and Liabilities, net		 -9.62 -26 -6.44 -45 13 -5.73 13 0.57 -53 12 10
Net Cash From Investing Activities		 105 -10 -26 -19 -34 -84 -55 -11 -4.29 11 -64
Net Cash From Continuing Investing Activities		 105 -10 -26 -19 -34 -84 -55 -11 -4.29 11 -64
Purchase of Property, Plant & Equipment		 -1.78 -1.85 -1.26 -1.13 -1.05 -0.80 -6.20 -1.90 -1.70 -2.14 -7.15
Purchase of Investments		 -106 -83 -88 -113 -113 -143 -138 -114 -98 -72 -160
Sale of Property, Plant & Equipment		 - - 0.00 - - - 0.44 - - - 0.00
Sale and/or Maturity of Investments		 113 75 64 95 79 60 89 105 96 86 104
Net Cash From Financing Activities		 13 2.62 11 11 3.37 2.43 -12 1.80 3.71 16 -10
Net Cash From Continuing Financing Activities		 13 2.62 11 11 3.37 2.43 -12 1.80 3.71 16 -10
Other Financing Activities, net		 14 2.61 11 11 3.37 2.43 -12 1.80 3.71 16 -10
Effect of Exchange Rate Changes		 0.01 -0.14 0.19 -0.34 0.29 -0.59 0.17 1.06 -0.31 -0.64 -1.33
Cash Income Taxes Paid		 - - 0.00 - 3.15 0.52 0.40 13 0.02 1.80 0.63

Annual Balance Sheets for Krystal Biotech

This table presents Krystal Biotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 2.18 50 116 209 311 626 558 818 1,056 1,334
Total Current Assets		 2.17 50 113 196 275 442 384 588 742 1,025
Cash & Equivalents		 1.92 50 104 188 268 341 162 358 345 496
Short-Term Investments		 - 0.00 8.09 6.17 2.99 97 217 174 253 331
Accounts Receivable		 - - - - - - 0.00 42 105 127
Inventories, net		 - - - - - - 0.00 6.99 27 40
Prepaid Expenses		 0.25 0.32 0.89 2.20 3.80 4.17 4.61 6.71 12 15
Current Deferred & Refundable Income Taxes		 - - - - - - - - 1.62 14
Plant, Property, & Equipment, net		 0.01 0.20 3.01 8.48 31 112 162 161 155 151
Total Noncurrent Assets		 0.00 0.00 0.45 4.67 4.91 72 13 69 159 158
Long-Term Investments		 - - - 0.50 0.00 64 4.62 62 152 128
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - 0.00 23
Other Noncurrent Operating Assets		 - - 0.45 4.17 4.91 7.30 8.37 7.29 6.51 7.53
Total Liabilities & Shareholders' Equity		 2.18 50 116 209 311 626 558 818 1,056 1,334
Total Liabilities		 1.89 0.64 2.89 6.11 19 33 36 40 109 114
Total Current Liabilities		 0.04 0.64 2.60 3.33 15 26 29 33 102 103
Accounts Payable		 0.04 0.64 2.60 1.02 2.11 25 27 26 64 43
Accrued Expenses		 - - - 1.83 5.11 - - 5.98 37 58
Other Current Liabilities		 - - - 0.48 8.24 1.04 1.56 1.47 1.22 1.77
Total Noncurrent Liabilities		 1.85 0.00 0.29 2.78 3.31 6.98 7.37 6.62 7.46 11
Other Noncurrent Operating Liabilities		 - 0.00 0.29 2.78 3.31 6.98 7.37 6.62 7.46 11
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.29 49 113 203 292 594 522 779 946 1,220
Total Preferred & Common Equity		 0.29 49 113 203 292 594 522 779 946 1,220
Total Common Equity		 -1.12 49 113 203 292 594 522 779 946 1,220
Common Stock		 0.03 59 133 242 363 735 804 1,048 1,127 1,194
Retained Earnings		 -1.15 -9.07 -20 -39 -71 -141 -281 -270 -181 24
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 0.00 0.01 0.01 -0.16 -0.73 0.64 -0.19 1.14

Quarterly Balance Sheets for Krystal Biotech

This table presents Krystal Biotech's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 12/31/2022 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 558 684 790 853 918 982 1,074 1,138 1,240 1,397
Total Current Assets		 384 484 582 602 683 713 767 841 926 1,020
Cash & Equivalents		 162 276 373 359 346 374 309 354 393 501
Short-Term Investments		 217 202 189 179 214 214 308 328 338 322
Accounts Receivable		 - - 9.32 46 103 97 103 111 130 127
Inventories, net		 - - 5.28 11 12 19 30 31 38 43
Prepaid Expenses		 4.61 6.49 5.47 6.49 7.75 8.96 17 17 17 16
Current Deferred & Refundable Income Taxes		 - - - - - - - - 10 11
Plant, Property, & Equipment, net		 162 164 164 160 159 157 151 150 149 154
Total Noncurrent Assets		 13 36 44 91 76 113 157 147 166 224
Long-Term Investments		 4.62 28 37 84 69 106 148 139 133 193
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - 25 23
Other Noncurrent Operating Assets		 8.37 7.88 7.65 7.04 6.79 6.67 8.08 7.85 7.78 7.34
Total Liabilities & Shareholders' Equity		 558 684 790 853 918 982 1,074 1,138 1,240 1,397
Total Liabilities		 36 31 34 54 79 96 90 98 102 120
Total Current Liabilities		 29 24 28 48 72 90 79 87 91 108
Accounts Payable		 27 22 26 35 49 59 31 34 34 35
Accrued Expenses		 - - - 11 22 30 47 52 56 71
Other Current Liabilities		 1.56 1.53 1.50 1.43 1.36 1.29 1.36 1.62 1.70 1.80
Total Noncurrent Liabilities		 7.37 7.01 6.82 6.47 6.91 6.95 10 11 11 12
Other Noncurrent Operating Liabilities		 7.37 7.01 6.82 6.47 6.91 6.95 10 11 11 12
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 522 653 756 799 839 886 985 1,041 1,138 1,277
Total Preferred & Common Equity		 522 653 756 799 839 886 985 1,041 1,138 1,277
Total Common Equity		 522 653 756 799 839 886 985 1,041 1,138 1,277
Common Stock		 804 1,013 1,035 1,068 1,093 1,110 1,129 1,146 1,164 1,198
Retained Earnings		 -281 -359 -279 -269 -253 -226 -145 -107 -27 80
Accumulated Other Comprehensive Income / (Loss)		 -0.73 -0.24 -0.38 -0.30 -0.63 1.51 0.39 1.16 1.10 -1.62

Annual Metrics And Ratios for Krystal Biotech

This table displays calculated financial ratios and metrics derived from Krystal Biotech's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 473.02% 33.94%
EBITDA Growth		 0.00% -587.89% -36.10% -95.30% -44.42% -116.08% -116.49% 95.77% 1,307.02% 131.63%
EBIT Growth		 0.00% -588.70% -37.49% -102.78% -45.68% -112.25% -112.66% 93.30% 775.39% 145.32%
NOPAT Growth		 0.00% -317.50% -149.71% -85.31% -49.45% -106.90% -112.66% 8.49% 166.04% 183.64%
Net Income Growth		 0.00% -588.70% -37.49% -75.30% -68.52% -116.28% -101.20% 107.81% 715.58% 129.74%
EPS Growth		 0.00% -12.98% 34.46% -23.71% -42.50% -83.04% -75.40% 107.10% 669.23% 128.00%
Operating Cash Flow Growth		 0.00% -196.72% -142.80% -97.88% -39.56% -83.79% -109.79% 11.70% 238.98% 62.75%
Free Cash Flow Firm Growth		 0.00% 0.00% -229.96% -129.00% -54.86% -370.06% 38.55% -36.84% 135.37% 118.17%
Invested Capital Growth		 0.00% -154.17% 1,352.14% 496.04% 138.46% 564.87% 0.00% 33.28% 6.63% 34.03%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 492.55% 20.29% 4.28%
EBITDA Q/Q Growth		 0.00% 0.00% -26.73% -8.59% -12.13% -20.54% -9.53% 95.85% 124.97% 1.92%
EBIT Q/Q Growth		 0.00% 0.00% -26.99% -9.62% -11.94% -20.17% -9.75% 93.41% 139.31% 1.96%
NOPAT Q/Q Growth		 0.00% 0.00% -29.56% -9.62% -14.84% -20.17% -9.75% 10.00% 123.76% 3.59%
Net Income Q/Q Growth		 0.00% 0.00% -26.99% -9.46% -18.52% -19.65% -7.90% 136.67% 70.24% 2.98%
EPS Q/Q Growth		 0.00% 0.00% -76.36% -0.84% -17.12% -15.07% -5.37% 126.90% 44.23% 2.40%
Operating Cash Flow Q/Q Growth		 0.00% -48.25% -17.27% -22.90% -4.09% -36.72% -1.44% 14.53% 94.84% 14.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -22.56% -13.40% -135.21% 45.10% -13.78% 817.93% 24.53%
Invested Capital Q/Q Growth		 0.00% 0.00% 73,350.00% 96.76% 35.60% 201.56% 0.00% 17.27% 2.67% -3.65%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 93.90% 93.09% 94.08%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11.83% 24.92% 43.13%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -216.43% 22.61% 41.45%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -19.19% 22.61% 41.45%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 21.56% 30.69% 52.64%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 84.76% 93.50% 108.11%
Interest Burden Percent		 100.00% 100.00% 100.00% 86.45% 100.00% 101.90% 96.40% -132.59% 145.15% 117.47%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 15.24% 6.50% -8.11%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -57.60% 32.22% 75.74%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -78.86% 28.09% 72.17%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 59.28% -21.89% -56.83%
Return on Equity (ROE)		 -397.92% -31.83% -13.39% -12.08% -13.00% -17.09% -26.80% 1.68% 10.34% 18.91%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -677.35% -445.69% -238.14% -207.72% -73.42% -86.13% 25.80% 46.66%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.41% 7.01% 13.50%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.59% 9.51% 17.14%
Return on Common Equity (ROCE)		 1,538.00% -30.93% -13.39% -12.08% -13.00% -17.09% -26.80% 1.68% 10.34% 18.91%
Return on Equity Simple (ROE_SIMPLE)		 -397.92% -16.01% -9.62% -9.41% -11.01% -13.32% -26.80% 1.40% 9.42% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.80 -3.34 -8.34 -15 -23 -48 -102 -93 61 174
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -183.45% 21.14% 44.81%
Net Nonoperating Expense Percent (NNEP)		 -479.32% -18.44% -3.16% -2.37% -3.90% -6.65% -9.99% 21.26% 4.13% 3.57%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -19.46% -11.95% 6.49% 14.30%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.10% 6.91% 5.92%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 194.09% 39.13% 37.71%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 91.58% 18.44% 14.92%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 310.33% 70.48% 52.63%
Earnings before Interest and Taxes (EBIT)		 -1.15 -7.92 -11 -22 -32 -68 -145 -9.73 66 161
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.15 -7.90 -11 -21 -30 -66 -142 -6.00 72 168
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 2.18 2.65 4.72 4.05 2.98 3.91 4.49 4.76 5.86
Price to Tangible Book Value (P/TBV)		 0.00 2.18 2.65 4.72 4.05 2.98 3.91 4.49 4.76 5.86
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 69.02 15.51 18.37
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 320.09 50.53 34.90
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.31% 1.98% 2.87%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 128.38 87.54 43.76 8.46 11.96 15.75 19.09 23.49
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 57.30 12.93 15.92
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 51.87 36.90
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 57.17 38.40
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 61.15 35.52
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30.43 30.83
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 76.36 57.66
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 6.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 6.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.25 -1.00 -0.99 -0.97 -0.94 -0.80 -0.73 -0.75 -0.78 -0.79
Leverage Ratio		 7.55 1.05 1.02 1.03 1.05 1.07 1.07 1.06 1.09 1.10
Compound Leverage Factor		 7.55 1.05 1.02 0.89 1.05 1.09 1.03 -1.40 1.58 1.30
Debt to Total Capital		 86.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 86.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 65.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -52.39% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -1.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -1.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -2.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -2.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 101.37 62.84 94.64 38.16 25.42 32.99 53.24 25.67 39.09
Noncontrolling Interest Sharing Ratio		 486.51% 2.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 50.44 77.99 43.39 58.88 17.80 13.30 13.30 17.76 7.28 9.95
Quick Ratio		 44.72 77.49 43.05 58.22 17.56 13.14 13.14 17.35 6.89 9.28
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -3.01 -9.92 -23 -35 -165 -102 -139 49 107
Operating Cash Flow to CapEx		 -8,740.00% -1,852.38% -422.78% -292.08% -175.73% -70.15% -189.83% -752.64% 2,912.22% 1,744.23%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -110.86 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -32.13 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -77.93 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.31 0.33
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.96 3.35
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.20 0.69
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.31 1.84 2.54
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.12 0.45 0.43
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 92.21 108.89
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 304.69 530.37
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3,122.02 815.27 846.93
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3,122.02 -418.36 -207.68
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.22 -0.12 1.47 8.73 21 138 138 185 197 264
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.31 1.52 1.69
Increase / (Decrease) in Invested Capital		 0.00 -0.33 1.58 7.27 12 118 0.00 46 12 67
Enterprise Value (EV)		 0.00 58 188 764 911 1,172 1,656 2,905 3,756 6,193
Market Capitalization		 0.00 108 300 959 1,182 1,556 2,040 3,499 4,506 7,149
Book Value per Share		 ($1.27) $4.83 $7.85 $11.72 $14.82 $23.48 $20.28 $27.61 $32.91 $42.06
Tangible Book Value per Share		 ($1.27) $4.83 $7.85 $11.72 $14.82 $23.48 $20.28 $27.61 $32.91 $42.06
Total Capital		 2.13 49 113 203 292 522 522 779 946 1,220
Total Debt		 1.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 1.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.08 -50 -112 -194 -271 -384 -384 -594 -750 -956
Capital Expenditures (CapEx)		 0.02 0.21 2.23 6.40 15 68 53 12 4.24 12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.20 -0.32 -1.71 -1.13 -12 -24 -24 23 43 94
Debt-free Net Working Capital (DFNWC)		 2.13 49 110 193 260 355 355 555 640 922
Net Working Capital (NWC)		 2.13 49 110 193 260 355 355 555 640 922
Net Nonoperating Expense (NNE)		 0.35 4.58 2.55 3.63 9.07 22 38 -104 -28 -30
Net Nonoperating Obligations (NNO)		 -0.07 -50 -112 -194 -271 -384 -384 -594 -750 -956
Total Depreciation and Amortization (D&A)		 0.00 0.02 0.14 1.09 1.85 2.77 3.39 3.73 6.71 6.55
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 44.65% 14.64% 24.12%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,094.33% 220.32% 236.85%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,094.33% 220.32% 236.85%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.31) ($1.48) ($0.97) ($1.20) ($1.71) $0.00 $0.00 $0.40 $3.12 $7.08
Adjusted Weighted Average Basic Shares Outstanding		 877.49K 10.31M 11.20M 17.36M 22.19M 0.00 0.00 27.15M 28.59M 28.94M
Adjusted Diluted Earnings per Share		 ($1.31) ($1.48) ($0.97) ($1.20) ($1.71) $0.00 $0.00 $0.39 $3.00 $6.84
Adjusted Weighted Average Diluted Shares Outstanding		 877.49K 10.31M 11.20M 17.36M 22.19M 0.00 0.00 27.75M 29.74M 29.95M
Adjusted Basic & Diluted Earnings per Share		 ($1.31) ($1.48) ($0.97) ($1.20) ($1.71) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 877.49K 5.36M 11.20M 15.90M 18.79M 0.00 0.00 28.29M 28.81M 29.23M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.80 -3.34 -8.34 -15 -23 -48 -84 -82 96 113
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -162.55% 33.21% 29.02%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 25.44% 32.82% 48.69%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -45.76 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -32.03 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -91.56 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -77.83 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Krystal Biotech

This table displays calculated financial ratios and metrics derived from Krystal Biotech's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 29,232,189.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 29,232,189.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 1.91
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 879.91% 116.26% 94.88% 36.65% 16.65% 17.52% 31.95%
EBITDA Growth		 347.32% 107.73% 105.35% 149.40% -68.21% 926.93% 845.04% 285.85% 79.68% 7.24% 46.27%
EBIT Growth		 335.31% 109.02% 101.91% 142.17% -69.69% 737.90% 641.25% 358.87% 84.11% 7.35% 48.10%
NOPAT Growth		 -18.07% 112.89% 80.44% 131.21% 178.80% 1,219.09% 543.62% 287.58% 233.65% 15.34% 64.49%
Net Income Growth		 370.51% 127.12% 102.06% 146.88% -66.34% 423.23% 3,734.01% 146.23% 192.00% 13.02% 56.53%
EPS Growth		 338.46% 149.59% 101.70% 142.40% -67.38% 150.82% 3,900.00% 143.40% 192.31% 10.46% 52.50%
Operating Cash Flow Growth		 -7.81% 67.61% 160.74% 87.81% 377.29% 830.68% 94.92% 1,365.09% -32.62% 46.68% 159.56%
Free Cash Flow Firm Growth		 60.82% -76.40% 63.80% -314.37% 69.21% 167.87% 65.14% 111.08% 1.32% -184.13% 166.30%
Invested Capital Growth		 13.65% 33.28% 20.25% 0.00% 21.80% 6.63% 23.94% 4.70% 42.82% 34.03% 18.46%
Revenue Q/Q Growth		 0.00% 392.55% 7.37% 55.32% 19.29% 8.71% -3.24% 8.91% 1.83% 9.51% 8.64%
EBITDA Q/Q Growth		 306.10% -96.40% -54.42% 610.98% 32.64% 16.18% 35.82% 8.04% 5.57% 6.81% 20.31%
EBIT Q/Q Growth		 294.51% -95.76% -70.29% 1,621.57% 39.81% 17.17% 37.63% 8.65% 5.26% 7.40% 20.82%
NOPAT Q/Q Growth		 2.41% 112.07% -313.07% 224.35% 146.43% 102.03% -28.34% 8.64% 112.51% -34.75% 9.41%
Net Income Q/Q Growth		 343.14% -89.24% -89.28% 1,570.39% 74.59% 67.33% -21.43% 7.28% 107.04% -35.24% 8.82%
EPS Q/Q Growth		 323.20% -78.14% -95.08% 1,666.67% 71.70% 68.13% -21.57% 7.50% 106.20% -36.47% 8.28%
Operating Cash Flow Q/Q Growth		 37.92% 65.93% 319.69% -126.23% 1,512.12% -10.22% -41.39% 70.26% -24.79% 95.44% 3.71%
Free Cash Flow Firm Q/Q Growth		 -147.71% 4.35% 15.02% -452.78% 93.15% 310.84% -143.64% 275.72% -160.87% -63.81% 137.66%
Invested Capital Q/Q Growth		 0.00% 17.27% -4.08% 18.65% -8.74% 2.67% 11.49% 0.23% 24.49% -3.65% -1.47%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 92.66% 94.65% 91.45% 92.03% 94.57% 94.30% 92.54% 95.64% 93.84% 94.57%
EBITDA Margin		 880.93% 6.43% 5.62% 25.70% 28.58% 30.55% 42.88% 42.53% 44.10% 43.00% 47.63%
Operating Margin		 -303.80% 7.44% -14.77% 12.19% 26.76% 45.40% 41.02% 40.93% 42.30% 41.49% 46.14%
EBIT Margin		 864.97% 7.44% 2.06% 22.83% 26.76% 28.84% 41.02% 40.93% 42.30% 41.49% 46.14%
Profit (Net Income) Margin		 943.75% 20.63% 2.06% 22.15% 32.42% 49.90% 40.52% 39.91% 81.15% 47.99% 48.07%
Tax Burden Percent		 100.00% 81.56% 100.00% 97.03% 91.30% 93.56% 81.96% 81.95% 165.46% 100.52% 91.03%
Interest Burden Percent		 109.11% 339.72% 100.00% 100.00% 132.70% 184.93% 120.51% 119.00% 115.94% 115.07% 114.44%
Effective Tax Rate		 0.00% 0.00% 0.00% 2.97% 8.70% 0.00% 18.04% 18.05% -65.46% -0.52% 8.97%
Return on Invested Capital (ROIC)		 -17.58% 2.34% -8.74% 18.72% 33.82% 69.19% 56.58% 56.06% 112.27% 70.49% 73.16%
ROIC Less NNEP Spread (ROIC-NNEP)		 -39.31% 1.20% -10.09% 16.41% 32.78% 68.58% 55.70% 55.21% 110.87% 69.70% 72.37%
Return on Net Nonoperating Assets (RNNOA)		 30.21% -0.90% 7.84% -12.31% -25.81% -53.42% -43.33% -42.59% -85.37% -54.89% -57.03%
Return on Equity (ROE)		 12.63% 1.43% -0.90% 6.42% 8.00% 15.77% 13.25% 13.47% 26.89% 15.61% 16.13%
Cash Return on Invested Capital (CROIC)		 -82.66% -86.13% -60.08% -219.98% -3.93% 25.80% 27.82% 51.76% 37.08% 46.66% 64.07%
Operating Return on Assets (OROA)		 10.97% 0.55% 0.26% 4.14% 7.29% 8.94% 14.19% 14.30% 14.21% 13.51% 15.58%
Return on Assets (ROA)		 11.97% 1.52% 0.26% 4.01% 8.83% 15.47% 14.02% 13.95% 27.25% 15.63% 16.23%
Return on Common Equity (ROCE)		 12.63% 1.43% -0.90% 6.42% 8.00% 15.77% 13.25% 13.47% 26.89% 15.61% 16.13%
Return on Equity Simple (ROE_SIMPLE)		 -3.94% 0.00% 7.15% 12.63% 5.91% 0.00% 12.59% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -26 3.14 -6.68 8.31 20 41 30 32 68 45 49
NOPAT Margin		 -303.80% 7.44% -14.77% 11.83% 24.43% 45.40% 33.62% 33.54% 70.00% 41.71% 42.00%
Net Nonoperating Expense Percent (NNEP)		 21.73% 1.14% 1.35% 2.31% 1.04% 0.61% 0.88% 0.84% 1.40% 0.79% 0.79%
Return On Investment Capital (ROIC_SIMPLE)		 - 0.40% - - - 4.37% 3.01% 3.10% 6.02% 3.66% 3.83%
Cost of Revenue to Revenue		 0.00% 7.34% 5.35% 8.55% 7.97% 5.43% 5.70% 7.46% 4.36% 6.16% 5.43%
SG&A Expenses to Revenue		 276.96% 58.76% 57.59% 39.31% 34.25% 34.33% 37.11% 36.61% 38.42% 38.54% 35.25%
R&D to Revenue		 124.23% 26.98% 24.21% 22.17% 16.12% 14.84% 16.17% 15.00% 14.91% 13.81% 13.18%
Operating Expenses to Revenue		 401.19% 85.74% 109.43% 79.26% 65.27% 49.17% 53.27% 51.61% 53.34% 52.36% 48.42%
Earnings before Interest and Taxes (EBIT)		 74 3.14 0.93 16 22 26 36 39 41 44 54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 75 2.71 2.54 18 24 28 38 41 43 46 55
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.30 4.49 6.28 6.25 5.90 4.76 5.27 3.82 4.49 5.86 5.91
Price to Tangible Book Value (P/TBV)		 4.30 4.49 6.28 6.25 5.90 4.76 5.27 3.82 4.49 5.86 5.91
Price to Revenue (P/Rev)		 379.54 69.02 52.31 31.55 21.65 15.51 15.58 11.06 13.69 18.37 18.10
Price to Earnings (P/E)		 0.00 320.09 87.80 49.50 99.86 50.53 41.90 27.07 25.69 34.90 33.56
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.31% 1.14% 2.02% 1.00% 1.98% 2.39% 3.69% 3.89% 2.87% 2.98%
Enterprise Value to Invested Capital (EV/IC)		 16.84 15.75 24.84 21.98 23.67 19.09 20.19 14.34 15.51 23.49 25.15
Enterprise Value to Revenue (EV/Rev)		 309.57 57.30 45.82 27.77 18.78 12.93 13.28 8.77 11.38 15.92 15.66
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 140.92 51.87 38.41 21.65 25.78 36.90 35.25
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 165.22 57.17 40.79 22.63 26.83 38.40 36.56
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 165.22 61.15 45.42 26.02 25.22 35.52 33.68
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 71.60 30.43 31.97 16.13 24.09 30.83 26.11
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 76.36 80.33 28.33 49.21 57.66 42.56
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.77 -0.75 -0.78 -0.75 -0.79 -0.78 -0.78 -0.77 -0.77 -0.79 -0.79
Leverage Ratio		 1.06 1.06 1.06 1.09 1.08 1.09 1.08 1.09 1.10 1.10 1.09
Compound Leverage Factor		 1.15 3.60 1.06 1.09 1.43 2.01 1.30 1.30 1.27 1.27 1.25
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 57.30 53.29 56.16 40.60 33.29 25.54 35.72 25.48 31.18 38.81 38.97
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 21.10 17.76 12.66 9.50 7.97 7.28 9.65 9.68 10.14 9.95 9.46
Quick Ratio		 20.72 17.35 12.29 9.23 7.66 6.89 9.06 9.13 9.43 9.28 8.82
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -45 -43 -36 -202 -14 29 -13 22 -14 -22 8.39
Operating Cash Flow to CapEx		 -1,191.80% -391.55% 1,260.95% -368.52% 5,626.86% 6,597.13% 536.82% 2,769.38% 2,327.41% 3,623.56% 1,124.54%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.07 0.12 0.18 0.27 0.31 0.35 0.35 0.34 0.33 0.34
Accounts Receivable Turnover		 0.00 0.00 0.00 1.61 4.53 3.96 4.45 3.35 3.29 3.35 3.62
Inventory Turnover		 0.00 0.00 0.00 0.95 1.53 1.20 1.11 1.10 0.76 0.69 0.67
Fixed Asset Turnover		 0.05 0.31 0.59 1.05 1.51 1.84 2.14 2.32 2.44 2.54 2.74
Accounts Payable Turnover		 0.00 0.12 0.19 0.24 0.43 0.45 0.69 0.58 0.46 0.43 0.74
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 226.68 80.56 92.21 81.95 109.07 110.98 108.89 100.71
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 385.81 239.17 304.69 329.89 331.05 479.27 530.37 544.17
Days Payable Outstanding (DPO)		 0.00 3,122.02 1,894.82 1,544.55 849.77 815.27 528.03 631.14 788.58 846.93 494.84
Cash Conversion Cycle (CCC)		 0.00 -3,122.02 -1,894.82 -932.06 -530.04 -418.36 -116.19 -191.02 -198.33 -207.68 150.05
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 157 185 177 210 192 197 219 220 274 264 260
Invested Capital Turnover		 0.06 0.31 0.59 1.58 1.38 1.52 1.68 1.67 1.60 1.69 1.74
Increase / (Decrease) in Invested Capital		 19 46 30 210 34 12 42 9.87 82 67 40
Enterprise Value (EV)		 2,649 2,905 4,396 4,616 4,536 3,756 4,428 3,152 4,245 6,193 6,534
Market Capitalization		 3,247 3,499 5,019 5,244 5,230 4,506 5,194 3,972 5,109 7,149 7,551
Book Value per Share		 $27.00 $27.61 $28.25 $29.37 $30.83 $32.91 $34.18 $36.01 $39.31 $42.06 $43.68
Tangible Book Value per Share		 $27.00 $27.61 $28.25 $29.37 $30.83 $32.91 $34.18 $36.01 $39.31 $42.06 $43.68
Total Capital		 756 779 799 839 886 946 985 1,041 1,138 1,220 1,277
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -599 -594 -622 -629 -694 -750 -765 -821 -864 -956 -1,017
Capital Expenditures (CapEx)		 1.78 1.85 1.26 1.13 1.05 0.80 5.77 1.90 1.70 2.14 7.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.52 23 16 51 35 43 70 72 103 94 89
Debt-free Net Working Capital (DFNWC)		 555 555 555 611 624 640 687 754 834 922 912
Net Working Capital (NWC)		 555 555 555 611 624 640 687 754 834 922 912
Net Nonoperating Expense (NNE)		 -107 -5.56 -7.62 -7.26 -6.70 -4.10 -6.08 -6.12 -11 -6.73 -7.06
Net Nonoperating Obligations (NNO)		 -599 -594 -622 -629 -694 -750 -765 -821 -864 -956 -1,017
Total Depreciation and Amortization (D&A)		 1.37 -0.43 1.61 2.02 1.53 1.56 1.63 1.54 1.75 1.62 1.73
Debt-free, Cash-free Net Working Capital to Revenue		 -87.94% 44.65% 17.09% 30.87% 14.62% 14.64% 21.13% 20.17% 27.69% 24.12% 21.22%
Debt-free Net Working Capital to Revenue		 6,481.36% 1,094.33% 578.08% 367.51% 258.22% 220.32% 206.12% 210.03% 223.60% 236.85% 218.53%
Net Working Capital to Revenue		 6,481.36% 1,094.33% 578.08% 367.51% 258.22% 220.32% 206.12% 210.03% 223.60% 236.85% 218.53%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $2.88 $0.53 $0.03 $0.54 $0.95 $1.60 $1.24 $1.33 $2.74 $1.77 $1.91
Adjusted Weighted Average Basic Shares Outstanding		 28.04M 27.15M 28.30M 28.60M 28.72M 28.59M 28.82M 28.91M 28.95M 28.94M 29.29M
Adjusted Diluted Earnings per Share		 $2.79 $0.61 $0.03 $0.53 $0.91 $1.53 $1.20 $1.29 $2.66 $1.69 $1.83
Adjusted Weighted Average Diluted Shares Outstanding		 28.89M 27.75M 29.29M 29.64M 29.90M 29.74M 29.87M 29.75M 29.83M 29.95M 30.51M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 28.21M 28.29M 28.56M 28.73M 28.76M 28.81M 28.90M 28.94M 29.00M 29.23M 29.48M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 2.20 4.07 20 32 29 30 32 29 31 49
Normalized NOPAT Margin		 -212.66% 5.21% 9.00% 29.08% 38.04% 31.78% 33.62% 33.54% 29.61% 29.04% 42.00%
Pre Tax Income Margin		 943.75% 25.29% 2.06% 22.83% 35.51% 53.34% 49.44% 48.70% 49.05% 47.74% 52.80%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here are key takeaways from Krystal Biotech, Inc. (KRYS) across the last four years, focusing on revenue, profitability, cash flow, and balance sheet trends.

  • Top-line strength in Q4 2025: Operating revenue of $107.105 million and gross profit of $100.512 million, yielding a gross margin of about 94% for the quarter.
  • Strong quarterly profitability: Q4 2025 net income attributable to common shareholders of $51.4 million; basic earnings per share (EPS) of $1.77 and diluted EPS of $1.69.
  • Healthy cash generation: Q4 2025 net cash from continuing operating activities of $77.508 million, indicating robust cash flow from core operations.
  • Solid liquidity and balance sheet health: Cash & equivalents around $392.6 million (Q3 2025); total current assets about $925.7 million; total equity about $1.138 billion; total current liabilities roughly $91.3 million, implying a current ratio near 10x.
  • Earnings per share trend higher in 2025: Q4 2025 basic EPS $1.77 and diluted EPS $1.69, higher than earlier year quarters, supporting a rising earnings trend.
  • Revenue trajectory across four years: Revenue has risen in 2024–2025 after a dip in 2023, indicating a rebound in top-line growth.
  • Investing and financing activity signals: Net cash from continuing investing activities around $11.16 million in Q4 2025 and net financing inflows around $15.66 million, reflecting ongoing growth investment and modest financing activity.
  • Operating cash flow variability: While 2025 shows strong CFO, certain prior quarters (e.g., Q2 2024 CFO around –$4.17 million) indicate quarterly working-capital fluctuations.
  • Healthy leverage posture: Liabilities are modest relative to equity, and liquidity remains ample, reducing near-term solvency concerns.
  • Short-term working-capital dip in 2024: Q2 2024 net cash from continuing operating activities was negative (about –$4.17 million), signaling a temporary working-capital challenge during that period.
05/14/26 12:09 PM ETAI Generated. May Contain Errors.

Krystal Biotech Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Krystal Biotech's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Krystal Biotech's net income appears to be on an upward trend, with a most recent value of $204.83 million in 2025, falling from -$1.15 million in 2016. The previous period was $89.16 million in 2024. See where experts think Krystal Biotech is headed by visiting Krystal Biotech's forecast page.

Krystal Biotech's total operating income in 2025 was $161.30 million, based on the following breakdown:
  • Total Gross Profit: $366.08 million
  • Total Operating Expenses: $204.79 million

Over the last 9 years, Krystal Biotech's total revenue changed from $0.00 in 2016 to $389.13 million in 2025, a change of 38,913,000,000.0%.

Krystal Biotech's total liabilities were at $114.23 million at the end of 2025, a 4.4% increase from 2024, and a 5,934.5% increase since 2016.

In the past 9 years, Krystal Biotech's cash and equivalents has ranged from $1.92 million in 2016 to $496.30 million in 2025, and is currently $496.30 million as of their latest financial filing in 2025.

Over the last 9 years, Krystal Biotech's book value per share changed from -1.27 in 2016 to 42.06 in 2025, a change of -3,404.1%.


Related Companies

Financial statements for NASDAQ:KRYS last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
NNVC FDA = New Momentum Wave!
NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for its antiviral NV-387, targeting measl...
Equiscreen | Sponsoredtc pixel
Peptide Company Lands Exclusive MMA Wellness Partnership
A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...
The Tomorrow Investor | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
The system holding the dollar together is gone…
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
Millionaire warns: Move your money before May 15
Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2...
Brownstone Research | Sponsoredtc pixel